Sign In
Buy LGVN
$0.80
-0.0197 (-2.40%)
At Close: Jun 22, 2026
Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
09:15am, Monday, 09'th Jun 2025
MIAMI, June 09, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic agi
Longeveron® to Attend BIO International Convention 2025
09:15am, Tuesday, 20'th May 2025
Longeveron to host Alzheimer's disease program partnering meetings at BIO 2025 conference June 16-19. Positive Phase 2a data published in Nature Medicine.
Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient
07:15am, Monday, 12'th May 2025
Longeveron selected as a Top 40 Semifinalist based on the feasibility of its stem cell therapy Stem cell therapy laromestorcel being evaluated as potential treatment for Alzheimer's disease and HLHS,
Longeveron Inc. (LGVN) Q1 2025 Earnings Call Transcript
05:31pm, Friday, 09'th May 2025
Longeveron Inc. (NASDAQ:LGVN ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Derek Cole - Investor Relations-Advisory Solutions Joshua Hare - Co-Founder, Chief Science O
Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update
04:05pm, Thursday, 08'th May 2025
Longeveron announces Q1 2025 financial results & provides business update. Pivotal Phase 2 clinical trial achieves 95% enrollment. Expected full enroll Q2.
Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
08:30am, Friday, 02'nd May 2025
Longeveron (LGVN) will report Q1 2025 financial results and provide a business update on Thursday, May 8, 2025 after the U.S. financial markets close.
Phase 2a results demonstrated laromestrocel (Lomecel-B™) improved cognitive function, quality of life, and brain volume in the treatment of mild Alzheimer's disease This encouraging clinical trial d
Longeveron® to Present at the 37th Annual Roth Conference
09:25am, Wednesday, 05'th Mar 2025
MIAMI, March 05, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic ag
Longeveron Inc. (LGVN) Q4 2024 Earnings Call Transcript
07:04pm, Friday, 28'th Feb 2025
Longeveron Inc. (NASDAQ:LGVN ) Q4 2024 Earnings Conference Call February 28, 2025 4:30 PM ET Company Participants Derek Cole - IR, Advisory Solutions Wa'el Hashad - CEO Nataliya Agafonova - CMO Lisa L
Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update
04:04pm, Friday, 28'th Feb 2025
Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ (laromestrocel) in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease and orphan-designated indication, has achieved
Cellular therapy Lomecel-B™ has been granted an International Non-proprietary Name (INN) of “laromestrocel” on the INN List issued by the World Health Organization (WHO) Lomecel-B™ is a propri
Longeveron to Present at Biotech Showcase 2025
09:10am, Wednesday, 18'th Dec 2024
MIAMI, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic agi
Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024
09:05am, Monday, 02'nd Dec 2024
MIAMI, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic agi
Longeveron, Inc. (LGVN) Q3 2024 Earnings Call Transcript
10:37pm, Tuesday, 12'th Nov 2024
Longeveron, Inc. (NASDAQ:LGVN ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Derek Cole - IR, Advisory Solutions Wa'el Hashad - CEO Nataliya Agafonova - CMO Lisa
Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)
09:05am, Monday, 11'th Nov 2024
Longeveron has appointed Devin Blass as Chief Technology Officer (CTO) and SVP of CMC, effective Dec 2, adding capabilities ahead of potential BLA filing.
